Table 2 Change in outcome measures between baseline and 16 weeks for 74 dupilumab-treated patients with CRSwNP
Outcome | Baseline | Week 16 | P-value * |
|---|---|---|---|
Bilateral endoscopic NPS (scale 0–8) | |||
Median ± IQR | 5.0 ± 2.0 | 2.0 ± 2.5 | < 0.001 |
SNOT-22 score (scale 0–110) | |||
Median ± IQR | 54.5 ± 28.8 | 21.0 ± 26.5 | < 0.001 |
Nasal congestion or obstruction score (scale 0–3) | |||
Median ± IQR | 3.0 ± 1.0 | 1.0 ± 0 | < 0.001 |
Missing, n (%) | 5 (6.8) | 5 (6.8) | |
Loss-of-smell score (scale 0–3) | |||
Median ± IQR | 3.0 ± 1.0 | 1.0 ± 2.0 | < 0.001 |
Missing, n (%) | 5 (6.8) | 5 (6.8) | |
Anterior/posterior rhinorrhea score (scale 0–3) | |||
Median ± IQR | 2.0 ± 1.0 | 1.0 ± 1.0 | < 0.001 |
Missing, n (%) | 5 (6.8) | 5 (6.8) | |
Patient reported total symptom score (scale 0–9) | |||
Median ± IQR | 8.0 ± 2.0 | 3.0 ± 3.0 | < 0.001 |
Missing, n (%) | 5 (6.8) | 5 (6.8) | |
Rhinosinusitis disease severity (VAS 0–10 cm) | |||
Median ± IQR | 9.0 ± 2.8 | 2.0 ± 2.8 | < 0.001 |
Missing, n (%) | 16 (21.6) | 16 (21.6) | |
Smell (VAS 0–10 cm) | |||
Median ± IQR | 9.0 ± 2.0 | 2.0 ± 4.0 | < 0.001 |
Missing, n (%) | 15 (20.3) | 15 (20.3) | |
Total IgE (KUA/L)† | |||
Median ± IQR | 451.5 ± 286.817 (23) | 210.0 ± 372.0 | < 0.001 |
Missing, n (%) | 17 (23) | ||
Eosinophils (cells/mm3)‡ | |||
Median ± IQR | 550.0 ± 500.0 | 481.0 ± 500.0 | > 0.05 |
Missing, n (%) | 13 (17.6) | 13 (17.6) |